Stay updated on Johnson & Johnson Press Releases

Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Johnson & Johnson Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    The FDA has received its first submission for nipocalimab to treat antibody positive generalized myasthenia gravis, marking a significant advancement in treatment options, while DePuy Synthes has launched a new fixation system for cardiac surgery, enhancing patient care.
    Difference
    100%
    Check dated 2024-09-04T06:03:42.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The European Commission has approved RYBREVANT® (amivantamab) and BALVERSA® (erdafitinib) for advanced lung and bladder cancers, respectively, highlighting significant advancements in treatment options for patients with specific mutations and conditions.
    Difference
    100%
    Check dated 2024-08-28T03:20:36.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The website now features 1,984 results and highlights the acquisition of V-Wave, which offers a novel treatment for heart failure, alongside the approval of RYBREVANT® plus LAZCLUZE™ as a first-line chemotherapy-free option for advanced lung cancer, showing significant efficacy compared to osimertinib.
    Difference
    100%
    Check dated 2024-08-21T01:36:21.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Recent updates include the launch of the TriLEAP™ Lower Extremity Anatomic Plating System by DePuy Synthes, a groundbreaking study on nipocalimab for severe fetal anemia, and a labeling amendment for the LINX™ Reflux Management System to include patients with Barrett’s Esophagus, while notable deletions include the approval of new cancer therapies and quarterly financial results from Johnson & Johnson.
    Difference
    100%
    Check dated 2024-08-14T00:47:13.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The latest updates highlight significant advancements in cancer treatment, including a new combination therapy for NSCLC that improves progression-free survival and a quadruplet therapy study for multiple myeloma that shows a 60% reduction in disease progression risk.
    Difference
    100%
    Check dated 2024-08-06T23:22:39.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The website now shows an increase to 1,975 results, and Johnson & Johnson has announced their participation in the 2024 Wells Fargo Healthcare Conference on July 29, 2024.
    Difference
    11%
    Check dated 2024-07-29T21:54:56.000Z thumbnail image

Stay in the know with updates to Johnson & Johnson Press Releases

Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.